0
No votes yet
Advanced Practice Nursing Issues

The Need for Routine Monitoring of Cardiac Function in Patients Receiving 5-Fluorouracil Infusion

Nataya Francis
CJON 2014, 18(3), 360-362 DOI: 10.1188/14.CJON.360-362

Fluorouracil (5-FU) is an antimetabolite that has become the cornerstone chemotherapeutic agent used to treat tumors of the gastrointestinal tract. Although proven to be effective, 5-FU can cause cardiotoxicity, which can be life-threatening. Adverse cardiac-related events induced by 5-FU include angina pectoris, myocardial infarction, supraventricular tachycardia, and atrial fibrillation. Nurses play a crucial role in the routine monitoring of cardiac function by identifying patients at high risk of developing 5-FU-related cardiotoxicity, monitoring patients during treatment, and then implementing specific interventions if 5-FU-related cardiotoxicity is identified or suspected. This article discusses the relevance of 5-FU-related cardiotoxicity, highlights the need for routine monitoring of cardiac function, and discusses methods of early detection and management.

References 

Aziz, S.A., Tramboo, N.A., Mohi-ud-Din, K., Iqbal, K., Jalal, S., & Ahmad, M. (1998). Supraventricular Arrhythmia: A complication of 5-Fluorouracil. <i>Clinical Oncology, 10</i>, 377-378.

Ceyhan, C., Meydan, N., Barutca, S., Tekten, T., Onbasili, A.O., Ozturk, B., … Bayrak, I. (2004). Influence of high dose leucovorin and 5-fluorouracil chemotherapy regimen on p wave duration and dispersion. <i>Journal of Clinical and Therapeutics, 29</i>, 267-271. doi:10.1111/j.1365-2710.2004.00556.x

Deboever, G., Hiltrop, N., Cool, M., & Lambrecht, G. (2013). Alternative treatment options in colorectal cancer patients with 5-fluorouracil- or capecitabine-induced cardiotoxicity. <i>Clinical Colorectal Cancer, 12</i>, 8-14. doi:10.1016/j.clcc.2012.09.003

De Forni, M., Malet-Martino, M.C., Jaillias, P., Shubiniski, R.E., Bachaud, J.M., Lemaire, L., … Soulie, P. (1992). Cardiotoxicity of high-dose continuous infusion fluorouracil: A prospective clinical trial. <i>Journal of Clinical Oncology, 10</i>, 1795-1801.

Grandi, A.M., Pinotti, G., Morandi, E., Zandi, P., Bulgheroni, P., Guasti, L., … Venco, A. (1997). Noninvasive evaluation of cardiotoxicity of 5-flurouracil and low doses of folinic acid: A one year follow up study. <i>Annals of Oncology, 8</i>, 705-708. doi:10.1023/A:1008263321681

Hrovatin, E., Viel, E., Lestuzzi, C., Tartuferi, L., Zardo, F., Brieda, M., … Nicolosi, G.L. (2006). Severe ventricular dysrhythmias and silent ischemia during infusion of the antimetabolite 5-fluorouracil and cisplatin. <i>Journal of Cardiovascular Medicine, 7</i>, 637-640. doi:10.2459/01.JCM.0000237914.12915.dd

Jensen, S.A., Hasbak, P., Mortensen, J., & Sørensen, J.B.(2010). Fluorouracil induces myocardial ischemia with increase of plasma brain natriuretic peptide and lactic acid but without dysfunction of left ventricle. <i>Journal of Clinical Oncology, 28</i>, 5280-5286. doi:10.1200/JCO.2009.27.3953

Jensen, S.A., & Sørensen, J.B. (2006). Risk factors and prevention of cardiotoxicity induced by 5-fluorouracil or capecitabine. <i>Cancer Chemotherapy and Pharmacology, 58</i>, 487-493. doi:10.1007/s00280-005-0178-1

Jensen, S.A., & Sørensen, J.B. (2012). 5-fluorouracil based therapy induces endovascular injury having potential significance to development of clinically overt cardiotoxicity. <i>Cancer Chemotherapy and Pharmacology, 69</i>, 57-64. doi:10.1007/s00280-011-1669-x

Kosmas, C., Kallistratos, M.S., Kopterides, P., Syrios, J., Skopelitis, H., Mylonakis., … Tsavaris, N. (2008). Cardiotoxicity of fluoropyrimidines in different schedules of administration: A prospective study. <i>Journal of Cancer Research and Clinical Oncology, 134</i>, 75-82. doi:10.1007/s00432-007-0250-9

National Heart, Lung, and Blood Institute. (n.d.). How is angina treated? Retrieved from <a target="_blank" href='http://www.nhlbi.nih.gov/health//dci/Diseases/Angina/Angina_Treatments.h...

Oztop, I., Gencer, M., Okan, T., Yaren, A., Altekin, E., Turker, S., & Yilmaz, U. (2004). Evaluation of cardiotoxicity of a combined bolus plus infusional 5-fluorouracil/folinic acid treatment by echocardiography, plasma troponin I level, qt interval and dispersion in patients with gastrointestinal system cancers. <i>Japanese Journal of Clinical Oncology, 34</i>, 262-268. doi:10.1093/jjco/hyh047

Polk, A., Vaage-Nilsen, M., Vistisen, K., & Nielsen. (2013). Cardiotoxicity in cancer patients treated with 5-fluorouracil or capecitabine: A systematic review of incidence, manifestations and predisposing factors. <i>Cancer Treatment Reviews, 39</i>, 974-984. doi:10.1016/j.ctrv.2013.03.005

Robben, N.C., Pippas, A.W., & Moore, J.O. (1993). The syndrome of 5-fluorouracil cardiotoxicity. An elusive cardiopathy. <i>Cancer, 71</i>, 493-509.

Roth, A., Kolari, C., & Popovic, S. (1975). Cardiotoxicity of 5-FU. <i>Cancer Chemotherapy Reports, 59</i>, 1051-1052.

Schöber, C., Papageorgiou, E., Harstrick, E., Bokemeyer, C., Mugge, A., Stahl, M., … Schmoll, H.J. (1993). Cardiotoxicity of 5-fluorouracil in combination with folinic acid in patients with gastrointestinal cancer. <i>Cancer, 72</i>, 2242-2247.

Sorrentino, M.F., Kim, J., Foderaro, A.E., & Truesdell, A.G. (2012). 5-fluorouracil induced cardiotoxicity: Review of literature. <i>Cardiology Journal, 19</i>, 453-458. doi:10.5603/CJ.2012.0084

Steger, F., Hautmann, M.G., & Kölbl, O. (2012). 5-FU-induced cardiac toxicity- an underestimated problem in radiooncology. <i>Radiation Oncology, 7</i>, 212. doi:10.1186/1748-717X-7-212

Sudhoff, T., Enderle, M.D., Pahlke, M., Petz, C., Teschendorf, C., Graeven, U., … Schmiegel, W. (2004). 5-fluorouracil induces arterial vasocontractions. <i>Annals of Oncology, 15</i>, 661-664. doi:10.1093/annonc/mdh150

Tsavaris, N., Komas, C., Vadiaka, M., Efremidis, M., Zinelis, A., Beldecos, D., … Stamatelos, G. (2002). Cardiotoxicity following different doses and schedules of 5-fluorouracil administration for malignancy- a survey of 427 patients. <i>Medical Science Monitor, 8</i>, 151-157.

Tsibiribi, P., Descotes, J., Lombard-Bohas, C., Barel, C., Bui-Xuan, B., Belkhiria, M., … Timour, Q. (2006). Cardiotoxicity of 5-fluorouracil in 1350 patients with no prior history of heart disease. <i>Bulletin Du Cancer, 93</i>, E27-E30.

Weidmann, B., Jansen, W., Heider, A., & Neiderle, N. (1995). 5-fluorouracil cardiotoxicity with left ventricular dysfunction under different dosing regimens. <i>American Journal of Cardiology, 75</i>, 194-195. doi:10.1016/S0002-9149(00)80079-X

Yilmaz, U., Oztop, I., Ciloglu, A., Okan, T., Tekin, U., Yaren, A., … Kirimli, O. (2007). 5- fluorouracil increases the number and complexity of premature complexes in the heart: A prospective study using ambulatory ECG monitoring. <i>International Journal of Clinical Practice, 61</i>, 795-801. doi:10.1111/j.1742-1241.2007.01323.x